NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $180.99 +0.87 (+0.48%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$174.66 -6.33 (-3.50%) As of 10/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ligand Pharmaceuticals Stock (NASDAQ:LGND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$179.21▼$183.8150-Day Range$131.58▼$180.9952-Week Range$93.58▼$183.81Volume145,677 shsAverage Volume241,553 shsMarket Capitalization$3.55 billionP/E RatioN/ADividend YieldN/APrice Target$176.50Consensus RatingModerate Buy Company Overview Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas. The company’s product offerings center around several core platforms. Captisol® is a chemically modified cyclodextrin used to improve the solubility, stability and delivery of small-molecule drug candidates. Ligand’s research services portfolio includes antibody discovery and optimization through its OmniAb™ platform, as well as absorption, distribution, metabolism and excretion (ADME) testing services provided by its Cyprotex and Absorption Systems subsidiaries. Together, these technologies and services support early- and late-stage drug development programs for a broad range of partners worldwide. Founded in 1987 and headquartered in San Diego, California, Ligand has grown through strategic acquisitions and collaborations, establishing a global footprint that spans North America, Europe and Asia. The company’s leadership team is led by President and Chief Executive Officer John L. Higgins, whose experience in drug development and corporate transactions has guided Ligand’s transformation into a technology-focused partner for the biopharmaceutical industry. Ligand continues to seek new alliances and in-licensing opportunities aimed at expanding its platform capabilities and royalty revenue streams.AI Generated. May Contain Errors. Read More Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreLGND MarketRank™: Ligand Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 180th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Ligand Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth114.45% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is -45.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is -45.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.71% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 3.45%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.57 Percentage of Shares Shorted5.71% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 3.45%, indicating that investor sentiment is improving. News and Social Media3.5 / 5News Sentiment1.31 News SentimentLigand Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ligand Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest10 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows3 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,046,012.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGND Stock News HeadlinesJason Aryeh Sells 10,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 25, 2025 | insidertrades.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of StockSeptember 5, 2025 | insidertrades.comThe “Black Monday Trader” warns of 40% crashWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late. | Stansberry Research (Ad)Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292September 25, 2025 | globenewswire.comLigand Pharma Amends Credit Agreement for StabilitySeptember 16, 2025 | tipranks.comWhat Analysts Are Saying About Ligand Pharmaceuticals StockSeptember 3, 2025 | benzinga.comA Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure ShiftAugust 22, 2025 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Announces Participation in Upcoming Investor Conferences | ...August 19, 2025 | gurufocus.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $107.15 on January 1st, 2025. Since then, LGND shares have increased by 68.9% and is now trading at $180.99. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its earnings results on Thursday, August, 7th. The biotechnology company reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.06. The firm's revenue was up 14.7% compared to the same quarter last year. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' top institutional investors include GAMMA Investing LLC. Insiders that own company stock include John L Higgins, Todd C Davis, Jason Aryeh, Matthew E Korenberg, John W Kozarich, Andrew Reardon, John L Lamattina, Stephen L Sabba, Octavio Espinoza and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/07/2025Today10/03/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees80Year Founded1987Price Target and Rating Average Price Target for Ligand Pharmaceuticals$176.50 High Price Target$206.00 Low Price Target$143.00 Potential Upside/Downside-2.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.00) Trailing P/E RatioN/A Forward P/E Ratio104.62 P/E GrowthN/ANet Income-$4.03 million Net Margins-40.44% Pretax Margin-45.04% Return on Equity-9.21% Return on Assets-8.09% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.21 Sales & Book Value Annual Sales$167.13 million Price / Sales21.23 Cash Flow$1.61 per share Price / Cash Flow112.10 Book Value$43.95 per share Price / Book4.12Miscellaneous Outstanding Shares19,600,000Free Float18,225,000Market Cap$3.55 billion OptionableOptionable Beta0.95 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:LGND) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.